S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

Detalles Bibliográficos
Autores principales: Kater, Arnon, Dubois, Julie, Brieghel, Christian, Kersting, Sabina, Enggaard, Lisbeth, Veldhuis, Gerrit, Mous, Rogier, Mellink, Clemens, Dobber, Johan, Poulsen, Christian, Da Cunha-Bang, Caspar, Fredriksen, Hendrik, Janssens, Ann, Schjodt, Ida, Dompeling, Ellen, Ranti, Juha, Mattsson, Mattias, Bellido, Mar, Tran, Hoa, Nasserinejad, Kazem, Levin, Mark-David, Niemann, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428369/
http://dx.doi.org/10.1097/01.HS9.0000967504.10648.ed

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428369/
http://dx.doi.org/10.1097/01.HS9.0000967504.10648.ed

Ejemplares similares